Medidata Solutions Named One of Deloitte's 2012 Technology Fast 500™
New Customer Commitments and Expanding Platform Drive Continued Growth for Leading Clinical Development Technology Company
NEW YORK--(BUSINESS WIRE)-- Medidata Solutions (NAS: MDSO) , a leading global provider of cloud-based solutions that optimize the efficiency of clinical development, announced that it has been named to Deloitte's Technology Fast 500™ list, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.
According to Medidata, accelerating adoption of its expanding platform of cloud-based solutions by new and existing companies contributed to the company's ranking of 388, as well as its 193 percent growth in revenue from 2007-2011. Medidata's customer base includes global, mid-size and emerging pharmaceutical, medical device and biotech companies, as well as clinical research organizations, academic research institutions and government.
"For more than a decade, leading life science companies have benefited from streamlined activities, better use of resources and enhanced collaboration made possible by our cloud-based technology and data-driven solutions," said Tarek Sherif, chairman and CEO, Medidata Solutions. "Our inclusion in the Fast 500TM reflects the leadership role we have played in driving change in the clinical trials landscape. Organizations continue to look for, and we are delivering, new solutions for better optimizing their development processes to improve clinical, financial and operational results."
Medidata has been featured in the Deloitte Fast 500TM annually, since 2009. In 2011, the company was ranked #247 for having achieved 359 percent fiscal year revenue growth.
Connect with Medidata:
Read our blog: Geeks Talk Clinical
Follow us on Twitter: @Medidata
Find us on LinkedIn
About Deloitte's 2012 Technology Fast 500TM
Technology Fast 500, conducted by Deloitte & Touche LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies—both public and private—in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2007 to 2011.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.
About Medidata Solutions Worldwide
Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies, as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
Geoff Curtis, +1 312.233.1253
KEYWORDS: United States North America New York
The article Medidata Solutions Named One of Deloitte's 2012 Technology Fast 500™ originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.